Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McDonnell

Showing results (361-370 of 374) with videos related to

Pageof 38
Sort By:
Nature Communications|June 6, 2019
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancerLuigi Racioppi, Erik R Nelson, Wei Huang, et al.
Science Translational Medicine|December 16, 2016
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translationGray R Anderson, Suzanne E Wardell, Merve Cakir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.
Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.
Nature Communications|September 3, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cellsRachid Safi, Suzanne E Wardell, Paige Watkinson, et al.
NPJ Breast Cancer|January 3, 2025
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signalingXi Xiao Huang, Ley Moy Ng, Po-Hsien Lee, et al.
Scientific Data|November 2, 2019
The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathwaysScott A Ochsner, David Abraham, Kirt Martin, et al.
Journal of Medicinal Chemistry|March 23, 2018
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast CancerGeorge S Tria, Tinya Abrams, Jason Baird, et al.
Cells|January 21, 2023
SGC-CAMKK2-1: A Chemical Probe for CAMKK2Carrow Wells, Yi Liang, Thomas L Pulliam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Pageof 38

Showing results (361-370 of 374) with videos related to

Sort By:
Pageof 38
Nature Communications|June 6, 2019
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancerLuigi Racioppi, Erik R Nelson, Wei Huang, et al.
Science Translational Medicine|December 16, 2016
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translationGray R Anderson, Suzanne E Wardell, Merve Cakir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.
Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.
Nature Communications|September 3, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cellsRachid Safi, Suzanne E Wardell, Paige Watkinson, et al.
NPJ Breast Cancer|January 3, 2025
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signalingXi Xiao Huang, Ley Moy Ng, Po-Hsien Lee, et al.
Scientific Data|November 2, 2019
The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathwaysScott A Ochsner, David Abraham, Kirt Martin, et al.
Journal of Medicinal Chemistry|March 23, 2018
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast CancerGeorge S Tria, Tinya Abrams, Jason Baird, et al.
Cells|January 21, 2023
SGC-CAMKK2-1: A Chemical Probe for CAMKK2Carrow Wells, Yi Liang, Thomas L Pulliam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Pageof 38